Radiopharm Theranostics Ltd

Radiopharm Theranostics announced significant progress across its pipeline, highlighted by a successful End-of-Phase 2 meeting with the FDA for RAD101, paving the way for a Phase 3 imaging trial in recurrent brain metastases in 1Q27. The company also reported positive Phase 1 imaging data for RAD301 in pancreatic cancer and advanced RAD202 in its Phase 1 HER2+ solid tumor study. A partnership with Siemens Healthineers was established for RAD101 manufacturing. Financially, Radiopharm received a substantial R&D tax refund and an advance on future refunds, strengthening its cash position to $7.5 million.

Radiopharm Theranostics Ltd will hold an Extraordinary General Meeting (EGM) on September 11, 2026, to seek shareholder approval for various aspects of its approximately $18.5 million capital raise. The resolutions include ratifying previously issued shares and approving the issuance of new shares, attaching options, and warrants to fund drug manufacturing, clinical trials, and working capital. The capital raise comprises a two-tranche placement, a Share Purchase Plan (SPP), and a US Direct Registration Offering.

Radiopharm Theranostics reported positive Phase 2b clinical trial results for its imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint, and plans to initiate a Phase 3 trial in Q4 2026. The company also announced it raised approximately $12.5M through an institutional offer and launched a $6M Share Purchase Plan post-quarter end. For the quarter ended June 30, 2026, net cash outflows from operating activities were $14.97M, with closing cash at $4.1M, though the company received a $5.9M R&D Tax Incentive post-quarter.

Radiopharm Theranostics reported positive results from its Phase 2b clinical trial for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, early clinical signs for RAD 204 showed a RECIST-confirmed Partial Response in the first patient of the third cohort. Post-quarter, Radiopharm raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan, with $3 million already subscribed, bolstering its financial position despite a quarter-end cash balance of $4.1 million.

Radiopharm Theranostics Limited announced the closing of its registered direct offering, raising approximately US$4.1 million in gross proceeds. The company issued 1,281,646 American Depositary Shares (ADSs) at US$3.16 per ADS and concurrently issued unregistered warrants to purchase an equal number of ADSs at an exercise price of US$3.79, expiring in July 2029, subject to shareholder approval. Additionally, the company secured A$6.7 million (US$4.7 million) from an Australian private placement and plans a Share Purchase Plan to raise up to A$6 million (US$4.2 million), both also subject to shareholder approval. The capital raised will fund the RAD101 registrational Phase 3 study, RAD 204 dose escalation, other therapeutic programs, and general corporate purposes.

Radiopharm Theranostics Limited announced the quotation of 384,493,800 new ordinary fully paid shares on the Australian Securities Exchange (ASX) under the ticker RAD. These shares were issued on July 28, 2026, as part of a previously announced placement, with each share issued for AUD 0.015. The issuance also involved 1,281,646 American Depositary Shares (ADS) representing these underlying ordinary shares. Following this quotation, the total number of ordinary fully paid shares on issue will be 3,928,709,960.

Radiopharm Theranostics announced a series of capital raises, including a US$4.1 million registered direct offering of ADSs and concurrent private placement of warrants in the US. Additionally, the company secured firm commitments for an Australian private placement of A$6.7 million (US$4.7 million) and plans a Share Purchase Plan for up to A$6 million (US$4.2 million) for Australian and New Zealand shareholders. The total potential gross proceeds from these offerings could reach approximately US$13 million, which will be used to fund clinical studies, therapeutic programs, and strategic initiatives.

Radiopharm Theranostics Limited announced a capital raise totaling approximately US$8.8 million through a combination of offerings. This includes a US registered direct offering of American Depositary Shares (ADSs) and concurrent private placement of warrants, raising US$4.1 million. Additionally, the company secured A$6.7 million (US$4.7 million) from an Australian private placement and plans a Share Purchase Plan for up to A$6 million (US$4.2 million). The proceeds are intended to fund the RAD101 registrational study, progress therapeutic programs, and for general corporate purposes.

Radiopharm Theranostics Ltd announced a multi-faceted capital raise totaling approximately US$13.0 million. This includes a US$4.1 million registered direct offering of American Depositary Shares (ADSs) and a concurrent private placement of warrants. Additionally, the company secured A$6.7 million (US$4.7 million) from an Australian Placement and plans a Share Purchase Plan to raise up to A$6 million (US$4.2 million) for existing shareholders. A significant portion of the Australian capital raise and associated options will require shareholder approval at an extraordinary general meeting scheduled for September 11, 2026. The funds are intended to advance the RAD101 registrational study, progress therapeutic programs, and for general corporate purposes.

Radiopharm Theranostics announced positive initial clinical results from the first two patients in the third cohort of its Phase 1 trial for RAD204, an investigational PD-L1-targeted radiotherapeutic. The first patient achieved a RECIST-confirmed durable Partial Response, remaining progression-free beyond seven months, while the second patient showed early tumor shrinkage and remains progression-free. RAD204 was generally well-tolerated with no dose-limiting toxicities observed, reinforcing its safety profile at the highest dose level.